Literature DB >> 25841041

Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method.

Stefan Leucht1, Myrto Samara2, Stephan Heres2, Maxine X Patel3, Toshi Furukawa4, Andrea Cipriani5, John Geddes5, John M Davis6.   

Abstract

BACKGROUND: The concept of dose equivalence is important for many purposes. The classical approach published by Davis in 1974 subsequently dominated textbooks for several decades. It was based on the assumption that the mean doses found in flexible-dose trials reflect the average optimum dose which can be used for the calculation of dose equivalence. We are the first to apply the method to second-generation antipsychotics.
METHODS: We searched for randomized, double-blind, flexible-dose trials in acutely ill patients with schizophrenia that examined 13 oral second-generation antipsychotics, haloperidol, and chlorpromazine (last search June 2014). We calculated the mean doses of each drug weighted by sample size and divided them by the weighted mean olanzapine dose to obtain olanzapine equivalents.
RESULTS: We included 75 studies with 16 555 participants. The doses equivalent to 1 mg/d olanzapine were: amisulpride 38.3 mg/d, aripiprazole 1.4 mg/d, asenapine 0.9 mg/d, chlorpromazine 38.9 mg/d, clozapine 30.6 mg/d, haloperidol 0.7 mg/d, quetiapine 32.3mg/d, risperidone 0.4 mg/d, sertindole 1.1 mg/d, ziprasidone 7.9 mg/d, zotepine 13.2 mg/d. For iloperidone, lurasidone, and paliperidone no data were available.
CONCLUSIONS: The classical mean dose method is not reliant on the limited availability of fixed-dose data at the lower end of the effective dose range, which is the major limitation of "minimum effective dose methods" and "dose-response curve methods." In contrast, the mean doses found by the current approach may have in part depended on the dose ranges chosen for the original trials. Ultimate conclusions on dose equivalence of antipsychotics will need to be based on a review of various methods.
© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antipsychotic drugs; dose; equivalence; schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 25841041      PMCID: PMC4601707          DOI: 10.1093/schbul/sbv037

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  25 in total

Review 1.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

Review 2.  Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

Authors:  Stephan Heres; John Davis; Katja Maino; Elisabeth Jetzinger; Werner Kissling; Stefan Leucht
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

Review 3.  Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.

Authors:  Lisa Hartling; Ahmed M Abou-Setta; Serdar Dursun; Shima S Mousavi; Dion Pasichnyk; Amanda S Newton
Journal:  Ann Intern Med       Date:  2012-10-02       Impact factor: 25.391

4.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

Authors:  J P McEvoy; G E Hogarty; S Steingard
Journal:  Arch Gen Psychiatry       Date:  1991-08

5.  Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.

Authors:  Nancy C Andreasen; Marcus Pressler; Peg Nopoulos; Del Miller; Beng-Choon Ho
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

Review 6.  Risperidone dose for schizophrenia.

Authors:  Chunbo Li; Jun Xia; Jijun Wang
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

7.  A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.

Authors:  Stefan Leucht; Katja Komossa; Christine Rummel-Kluge; Caroline Corves; Heike Hunger; Franziska Schmid; Claudia Asenjo Lobos; Sandra Schwarz; John M Davis
Journal:  Am J Psychiatry       Date:  2008-11-17       Impact factor: 18.112

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

Review 9.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Authors:  S Leucht; D Arbter; R R Engel; W Kissling; J M Davis
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

Review 10.  Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.

Authors:  Jian-Ping Zhang; Juan A Gallego; Delbert G Robinson; Anil K Malhotra; John M Kane; Christoph U Correll
Journal:  Int J Neuropsychopharmacol       Date:  2012-12-03       Impact factor: 5.176

View more
  58 in total

1.  A Neural Signature of Parkinsonism in Patients With Schizophrenia Spectrum Disorders: A Multimodal MRI Study Using Parallel ICA.

Authors:  Robert C Wolf; Mahmoud Rashidi; Stefan Fritze; Katharina M Kubera; Georg Northoff; Fabio Sambataro; Vince D Calhoun; Lena S Geiger; Heike Tost; Dusan Hirjak
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

2.  Multimodal Magnetic Resonance Imaging Data Fusion Reveals Distinct Patterns of Abnormal Brain Structure and Function in Catatonia.

Authors:  Dusan Hirjak; Mahmoud Rashidi; Katharina M Kubera; Georg Northoff; Stefan Fritze; Mike M Schmitgen; Fabio Sambataro; Vince D Calhoun; Robert C Wolf
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

3.  The effect of bilateral transcranial direct current stimulation on early auditory processing in schizophrenia: a preliminary study.

Authors:  Walter Dunn; Yuri Rassovsky; Jonathan Wynn; Allan D Wu; Marco Iacoboni; Gerhard Hellemann; Michael F Green
Journal:  J Neural Transm (Vienna)       Date:  2017-07-07       Impact factor: 3.575

4.  Multiparametric mapping of white matter microstructure in catatonia.

Authors:  Jakob Wasserthal; Klaus H Maier-Hein; Peter F Neher; Georg Northoff; Katharina M Kubera; Stefan Fritze; Anais Harneit; Lena S Geiger; Heike Tost; Robert C Wolf; Dusan Hirjak
Journal:  Neuropsychopharmacology       Date:  2020-05-05       Impact factor: 7.853

5.  Dose Equivalents for Antipsychotic Drugs: The DDD Method.

Authors:  Stefan Leucht; Myrto Samara; Stephan Heres; John M Davis
Journal:  Schizophr Bull       Date:  2016-07       Impact factor: 9.306

6.  Connectomic Underpinnings of Working Memory Deficits in Schizophrenia: Evidence From a replication fMRI study.

Authors:  Jie Yang; Weidan Pu; Guowei Wu; Eric Chen; Edwin Lee; Zhening Liu; Lena Palaniyappan
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

7.  Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study.

Authors:  Juan Antonio García-Carmona; Jorge Simal-Aguado; María Pilar Campos-Navarro; Francisco Valdivia-Muñoz; Alejandro Galindo-Tovar
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

8.  Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study.

Authors:  Jennifer A Watt; Tara Gomes; Susan E Bronskill; Anjie Huang; Peter C Austin; Joanne M Ho; Sharon E Straus
Journal:  CMAJ       Date:  2018-11-26       Impact factor: 8.262

9.  Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.

Authors:  Jacob Spertus; Marcela Horvitz-Lennon; Sharon-Lise T Normand
Journal:  Med Decis Making       Date:  2019-08-02       Impact factor: 2.583

10.  Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.

Authors:  Zainab Al-Dhaher; Sandeep Kapoor; Ema Saito; Scott Krakower; Lisa David; Theodore Ake; John M Kane; Christoph U Correll; Maren Carbon
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-04-19       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.